



## Research Article

# *In vitro* Assessment of Antioxidant, Antimicrobial and Anticancer Properties of Lactic Acid Bacteria

<sup>1</sup>Mohamed Gamal Shehata, <sup>2</sup>Marwa Muhammad Abu-Serie, <sup>1</sup>Nourhan Mohammad Abd El-Aziz and <sup>1</sup>Sobhy Ahmed El-Sohaimy

<sup>1</sup>Department of Food Technology, Arid Lands Cultivation Research Institute, City of Scientific Research and Technological Applications, New Borg El-Arab City, P.O. Box 21934, Alexandria, Egypt

<sup>2</sup>Department of Medical Biotechnology, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications, New Borg El-Arab City, P.O. Box 21934, Alexandria, Egypt

## Abstract

**Background and Objectives:** Probiotic strains can be utilized as bio-preservatives and functional food supplements. The present study aimed to characterize the 8 lactic acid bacteria (LAB) strains and their probiotic properties and antioxidant and anticancer potential. The selected LAB strains displayed antimicrobial activity against foodborne pathogens. **Materials and Methods:** The *in vitro* probiotic characteristics of these 8 strains demonstrated superior acid and bile tolerance, simulated gastric juice (SGJ) tolerance and an *in vitro* ability to adhere to Caco-2 cells. The antioxidant effects of intracellular and cell-free extracts of LAB strains were assessed by several antioxidant assays including resistance to hydrogen peroxide, DPPH radical scavenging, ABTS radical scavenging and hydroxyl radical scavenging (HRS). **Results:** Findings showed that the bacterial lysate and cell-free supernatant (CFS) of *S. thermophilus* BLM 58, *L. lactis* subsp. *lactis* DSM 20481, *P. acidilactici* ATCC 8042 and *L. Brevis* NRRL B-4527 possessed excellent antioxidant capacities. **Conclusion:** The current study demonstrated for the first time that the high capacity of *S. thermophilus* BLM 58 to have anticancer effects against cancer cells from four types of cancerous cell lines. This may be a promising finding for future cancer treatments and in the prevention of cancer using natural probiotics.

**Key words:** Natural probiotics, lactic acid bacteria, antioxidant, anticancer, simulated gastric juice, hydroxyl radical scavenging, cancerous cell lines

**Received:** January 17, 2019

**Accepted:** April 25, 2019

**Published:**

**Citation:** Mohamed Gamal Shehata, Marwa Muhammad Abu-Serie, Nourhan Mohammad Abd El-Aziz and Sobhy Ahmed El-Sohaimy, 2019. *In vitro* assessment of antioxidant, antimicrobial and anticancer properties of lactic acid bacteria. Int. J. Pharmacol., CC: CC-CC.

**Corresponding Author:** Mohamed Gamal Shehata, Department of Food Technology, Arid Lands Cultivation Research Institute, City of Scientific Research and Technological Applications, New Borg El-Arab City, P.O. Box 21934, Alexandria, Egypt Tel: +21061087173

**Copyright:** © 2019 Mohamed Gamal Shehata *et al.* This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

**Competing Interest:** The authors have declared that no competing interest exists.

**Data Availability:** All relevant data are within the paper and its supporting information files.

## INTRODUCTION

Probiotics are living micro-organisms with both nutritional and health benefits<sup>1</sup>. Probiotic research was first conducted by Élie Metchnikoff 100 years ago<sup>2</sup>. Most probiotic micro-organisms are lactic acid bacteria (LAB), such as *Lactobacillus* sp., *Bifidobacterium* sp., *Enterococcus* sp., *Streptococcus thermophilus* and *Pediococcus acidilactici*<sup>3</sup>. Several functional properties of probiotics provide health benefits. These features include resistance to gastric juices and bile salts, adherence to human epithelial cells, antimicrobial activity against pathogenic micro-organisms and bile salt hydrolase activity. The capacity for resistance and growth in the low pH conditions of the stomach and high salt concentrations and pH of bile enable probiotics to survive in different gastrointestinal conditions<sup>4</sup>. Furthermore, probiotics can inhibit microbial growth, particularly foodborne pathogens, such as; *Listeria monocytogenes*, *Staphylococcus aureus*, *Staphylococcus aureus* and *Escherichia coli*<sup>5</sup>.

Identification of the antioxidative properties of probiotics against free radicals is an interesting research topic. Oxidative damage contributed to several human diseases (e.g., cancer, atherosclerosis, cirrhosis and inflammatory diseases)<sup>6,7</sup> and oxidative stress caused damage to cellular macromolecules including DNA. Elevated levels of oxidative DNA lesions have been observed in various tumors. The addition of probiotics to food is an exciting alternative to antibiotics and has generated significant public interest due to the emergence of antimicrobial resistance<sup>8</sup>. Artificial antioxidants, such as; butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA) and n-propyl gallate (PG), have strong antioxidant activities against numerous oxidation systems. However, the use of these antioxidants in food has been hindered in some countries due to their potential risks to human health<sup>9</sup>. Antioxidants from natural sources are likely to be more acceptable than those chemically produced due to the reported side effects of some artificial antioxidants<sup>10</sup>. Consequently, the search for natural, stable, safe, antimicrobial, antioxidant and anticancer agents have become a subject of interest as alternatives to artificial compounds. The present study aimed to characterize probiotic LAB strains and assess their antimicrobial, antioxidant and anticancer efficacies.

## MATERIALS AND METHODS

The current study was carried out in the City of Scientific Research and Technological Applications, Alexandria, Egypt from September, 2017-June, 2018.

Table 1: Strains and their growth conditions

Microorganisms	Media and growth temperature
<b>Lactic acid bacteria strains</b>	
<i>Lactobacillus brevis</i> NRRL B-4527	MRS Broth, 30°C*
<i>Streptococcus thermophilus</i> BLM 58	M17 Broth, 37°C
<i>Pediococcus acidilactici</i> ATCC 8042	MRS Broth, 30°C
<i>Lactobacillus rhamnosus</i> CCUG 1452	MRS Broth, 30°C
<i>Lactobacillus curvatus</i> ATCC 51436	MRS Broth, 30°C
<i>Lactococcus lactis</i> subsp. <i>lactis</i> DSM 20481	MRS Broth, 30°C
<i>Lactobacillus plantarum</i> DMSZ 20079	MRS Broth, 30°C
<i>Lactobacillus plantarum</i> TF103	MRS Broth, 30°C
<b>Pathogenic strains</b>	
<i>Candida albicans</i> ATCCMYA-2876	YPD Broth, 37°C**
<i>Clostridium botulinum</i> ATCC 3584	TPGY Broth, 37°C†
<i>Escherichia coli</i> BA 12296	LB Broth, 37°C‡
<i>Klebsiella pneumoniae</i> ATCC12296	LB Broth, 37°C‡
<i>Salmonella enterica</i> subsp. <i>enterica</i>	Nutrient Broth, 37°C
<i>Serovar senftenberg</i> ATCC 8400	
<i>Staphylococcus aureus</i> NCTC 10788	Nutrient Broth, 37°C

\*MRS Broth: deMan, Rogosa and Sharpe \*\*YPD broth: Yeast peptone dextrose, †TPGY broth: Tryptone-peptone-glucose-yeast extract, ‡LB broth: Luria-Bertani medium

**Micro-organism and growth conditions:** The strains used in this study and their growth conditions are listed in Table 1. All strains were maintained as frozen stocks at -20°C in 25% (v/v) glycerol and routinely propagated in MRS<sup>11</sup> broth with a pH of 6.8 for 20 h at 30°C for LAB strains and with a pH of 6.8 for 24 h at 37°C for pathogenic strains.

### Evaluation of functional properties of LAB strains

#### Qualitative and quantitative antimicrobial activity assays:

Qualitative antimicrobial activity assays of LAB strains were performed against 7 pathogens (Table 1). Strains were tested using the spot-on-lawn method<sup>12</sup>. Activity was quantified by taking the reciprocal of the highest dilution that exhibited a clear zone of inhibition and was expressed as activity units (AU) per milliliter of culture media. The titre of the antibacterial substance in AU/mL, was calculated as (1000/d) D, where, D is the dilution factor and d is the amount of supernatant<sup>13</sup> in µL.

#### In vitro resistance to simulated gastric juice (SGJ) and bile salt:

Acid tolerance was determined as described by Charteris *et al.*<sup>1</sup>, with some modifications. The LAB cells from 100 mL MRS culture were harvested by centrifugation (4300 g, 10 min) and washed three times in phosphate buffered saline, pH 7.0. Washed cell pellets were then suspended in (1/10) cultivation volume in the same buffer, hence, obtaining a 10-fold increase in cell density. To 1 mL of the washed cell suspension, 5 mL of simulated gastric juice and 1.5 mL NaCl (0.5 w/v) were added. Simulated gastric juice was prepared freshly daily by suspending pepsin (3 g L<sup>-1</sup>) in sterile saline (0.5% w/v) and adjusting the pH to 2.0 with concentrated HCl. The materials were vortexed for 10 sec and

incubated at 37°C for 3 h. Aliquots of 0.1 mL were then removed at constant intervals (0, 1, 2, 3 h) for determination of total viable count. Dilutions were made (up to 10<sup>-4</sup>) and cells were plated in duplicate on MRS agar. Plates were incubated at 37°C for 72 h before enumeration.

Bile salt tolerance was determined as described by Shehata *et al.*<sup>4</sup>. The MRS broth supplemented with 0.3% bile salt was prepared. A preparation without bile salt was used as a control. The cells from 100 mL (20 h MRS tested culture) were collected by centrifugation (3400 g, 10 min), washed twice in saline (8.5 g L<sup>-1</sup> NaCl) and resuspended in 10 mL MRS broth. This suspension was inoculated (1%) into MRS broth lacking or containing bile salt. After 0, 1, 2 and 3 h of incubation at 37°C, viable counts on MRS agar plates and absorbance of the culture at 625 nm were determined. Experiments of acid and bile tolerance were repeated three times each with duplicate analysis.

**In vitro cell adhesion assay:** The *in vitro* adhesion abilities of selected LAB strains were assayed using Caco-2 cells. Human Caucasian colon adenocarcinoma (Caco-2) was obtained from American Type Culture Collection (ATCC, USA). The Caco-2 cells were cultivated in DMEM (Lonza, USA) containing 10% fetal bovine serum (GIBCO, USA), seeded in 6-well plates and incubated in a 5% CO<sub>2</sub> incubator at 37°C for 24 h. After incubation, the Caco-2 cells (300,000 cell mL<sup>-1</sup>) were incubated with a 1 mL suspension of a LAB strain (1 × 10<sup>8</sup> CFU mL<sup>-1</sup>) for 2 h in a 5% CO<sub>2</sub> incubator. After washing the cells with sterile 1 × phosphate-buffered saline (PBS) (pH 7.4), cells were fixed and stained with 1 mL of Giemsa<sup>14</sup> solution (1 ×) at 37°C for 20 min. The wells were washed with absolute ethanol to remove excess stain, air dried and investigated under an inverted microscope (Olympus, Japan). To determine the percentage of adhesion of LAB strains to Caco-2 cells, bacterial cells were detached from the monolayer by adding 500 µL of trypsin-EDTA solution. Then, the detached cell suspension was serially diluted, plated onto an MRS agar plate and incubated at 30°C for 48 h. Subsequently, colonies were counted and the percentage of adherent bacterial cells was determined<sup>15</sup>. Experiments of adhesion assay were repeated three times each with duplicate analysis:

$$\text{Adhesion (\%)} = \frac{B_1}{B_0} \times 100$$

where, B is the number of viable LAB cells (CFU mL<sup>-1</sup>) before (B<sub>0</sub>) and after (B<sub>1</sub>) adhesion.

### **In vitro determination of antioxidant activity of LAB strains**

#### **Preparation of the culture supernatant and bacterial lysate**

**extract:** Bacterial lysate extracts were prepared according to a method by Lin and Yen<sup>16</sup>. The LAB strains were grown in MRS broth at 37°C for 18 h. The bacterial cells were harvested by centrifugation (4300 × g, 10 min, 4°C), washed twice and resuspended in deionized water. Bacterial counts in cell pellets were adjusted to 10<sup>8</sup>, 10<sup>9</sup> and 10<sup>10</sup> CFU mL<sup>-1</sup>.

#### **Antioxidant assays**

**Resistance to hydrogen peroxide:** A method by Buchmeier *et al.*<sup>17</sup> was used with some modifications. Overnight cultures of the LAB strains were inoculated at 1% (v/v) into MRS broth and MRS broth containing 0.4, 0.7 or 1.0 mM hydrogen peroxide (30 wt.% solution in water), followed by incubation at 30°C for 8 h. Cell growth (absorbance) was measured spectrophotometrically at 600 nm.

**Scavenging of hydroxyl radicals:** Hydroxyl radical scavenging (HRS) assays were conducted by a Fenton reaction method<sup>18</sup>. Briefly, a reaction mixture containing 1.0 mL of Brilliant Green (0.435 mM), 2.0 mL of FeSO<sub>4</sub> (0.5 mM), 1.5 mL of H<sub>2</sub>O<sub>2</sub> (3.0%, w/v) and 1.0 mL of bacterial lysate extract in different concentrations was incubated at room temperature for 20 min and the absorbance was measured at 624 nm. Changes in the absorbance of the reaction mixture indicated the scavenging ability of the LAB strains for hydroxyl radicals. HRS activity was expressed as follows:

$$\text{Scavenging activity (\%)} = \frac{A_s - A_0}{A - A_0} \times 100$$

where, A<sub>s</sub> is the absorbance of the sample, A<sub>0</sub> is the absorbance of the control and A is the absorbance without the sample or Fenton reaction system.

**Antioxidant capacity using the ABTS<sup>+</sup> method:** The antioxidant activity was determined by using the ABTS<sup>+</sup> radical cation method with some modifications as described by Rossini *et al.*<sup>19</sup>. All determinations were carried out at least three times. The percentage inhibition of absorbance at 734 nm was calculated by using an ascorbic acid standard curve:

$$\text{ABTS radical scavenging activity (\%)} = \frac{\text{Abs}_{\text{control}} - \text{Abs}_{\text{sample}}}{\text{Abs}_{\text{control}}} \times 100$$

where, Abs<sub>control</sub> is the absorbance of ABTS radical+methanol; Ab<sub>sample</sub> is the absorbance of ABTS radical+sample/standard.

**Scavenging ability for DPPH radicals:** The DPPH was used at a concentration of 60 mM in methyl alcohol. In the dark, 0.1 mL sample aliquots (culture supernatant or bacterial lysate extract) were transferred to test tubes containing 3.9 mL of DPPH radical solution and were homogenized by shaking. The absorbance of the solution at 517 nm was measured using a spectrophotometer. All of the tests were carried out in triplicates. The inhibition of DPPH radical was calculated as follows:

$$\text{Inhibition (\%)} = \frac{\text{Abs } 517_{\text{Control}} - \text{Abs } 517_{\text{sample}}}{\text{Abs } 517_{\text{Control}}} \times 100$$

where,  $A_{\text{control}}$  is the absorbance of the control solution,  $A_{\text{sample}}$  is the absorbance of the test extract.

The results are expressed as  $IC_{50}$  ( $\text{mg mL}^{-1}$ ), which is the minimum antioxidant concentration required to reduce 50% of the initial DPPH reaction from the time the extract reached stability<sup>20</sup>. All determinations were carried out at least three times.

**Cytotoxicity of probiotic lysates:** Normal human dermal fibroblast (HDF) cells were sustained as adherent cells in DMEM containing 10% fetal bovine serum (FBS). The cytotoxicity of bacterial lysate samples toward normal cells was determined using MTT assays as described by Mosmann<sup>21</sup>.

**Anticancer activity of probiotic lysates:** A colon cancer cell line (Caco-2) and a prostate cancer cell line (PC3) were maintained as adherent cell cultures in DMEM. A liver cancer cell line (HepG-2) and a breast cancer cell line (MCF-7) were cultured in RPMI 1640 medium (Lonza, USA). All media were supplemented with 10% FBS. The sensitivity of tumor cells to bacterial lysate samples was assessed using MTT assays as described by Mosmann<sup>21</sup>. Control untreated cancer cells which was incubated with culture medium without any addition of bacterial lysates. The anticancer activities of the bacterial lysates were expressed as  $IC_{50}$  values, i.e., values associated with 50% death of cancer cells and were estimated by GraphPad InStat software version 3.10. The selectivity index (SI) was estimated as the ratio of the  $IC_{50}$  of normal PBMCs to that of cancer cells. The most effective anticancer bacterial lysates were also investigated by phase contrast inverted microscopy (Olympus, Japan). All determinations were carried out at least three times.

**Flow cytometry analysis of the anticancer activity of probiotic lysates:** Human cancer cell lines (MCF-7, HepG-2 and Caco-2) were treated with  $IC_{50}$  doses of

the most potent anticancer bacterial lysates and incubated in a 5%  $\text{CO}_2$  incubator at 37°C for 72 h. Untreated and treated cancer cells were harvested by trypsinization, washed and resuspended in PBS. Then, the untreated and treated cells were stained with annexin V-biotin (Molecular Probes™, USA) and propidium iodide (PI) in dark for 15 min. Cell death rates were detected by Partec flow cytometry (ex = 488 nm, em = 530 nm) using a FITC signal detector (FL1) for annexin-stained apoptotic cells and a phycoerythrin signal detector (FL2) for PI-stained necrotic cells.

**Statistical analysis:** Data are expressed as the means  $\pm$  standard errors of the means (SEM) by multiple comparison tests and one-way analysis of variance (ANOVA) using the SPSS16 software package. Probability (p) values < 0.05 were considered significant. The correlation coefficient between antioxidant and anticancer activity was calculated by Pearson correlation using the SPSS16 software package.

## RESULTS

**Antimicrobial properties of LAB:** As shown in Table 2, the antimicrobial activity results of the LAB strain isolates in terms of activity units ( $\text{AU mL}^{-1}$ ) illustrated. The selected LAB strains showed antimicrobial activities against these pathogenic micro-organisms on several levels (Table 2). *Lactobacillus brevis*, *Pediococcus acidilactici* and *Lactobacillus plantarum* TF103 exerted strong inhibitory activity against *Klebsiella pneumoniae* ATCC12296 ( $6400 \text{ AU mL}^{-1}$ ), whereas, *Lactobacillus rhamnosus* CCUG 1452 showed slightly better inhibitory effects against *Salmonella enterica* subsp. *enterica* serovar senftenberg ATCC 8400 ( $3200 \text{ AU mL}^{-1}$ ). *Pediococcus acidilactici* ATCC 8042 showed moderate antimicrobial activities against *Escherichia coli* BA 12296 and *Staphylococcus aureus* NCTC 10788 ( $1600 \text{ AU mL}^{-1}$ ).

**Tolerance to acid and bile:** Expectation of the strain resistance to the gut conditions where in vitro to measure their tolerance to low pH, bile predicated and pancreatic fluid. In the present study, all selected LAB strains survived in SGJ at pH 2 and 0.3% bile after 3 h of incubation. *Pediococcus acidilactici* ATCC 8042, *L. plantarum* TF103 and *L. brevis* NRRL B-4527 exhibited acid resistance with  $78.94 \pm 0.7$ ,  $78.94 \pm 0.7$  and  $76.58 \pm 1.55\%$  of viability, respectively (Table 3). In case of bile tolerance *L. brevis* NRRL B-4527, *L. lactis* subsp. *lactis* DSM 20481, *L. plantarum* TF103, *P. acidilactici* ATCC 8042 showed a high surviving percentage  $75.24 \pm 2.48$ ,  $75.21 \pm 2.18$ ,  $74.38 \pm 2.1$  and  $71.72 \pm 3.23\%$ , respectively (Table 4).

Table 2: Antimicrobial activities of cell-free supernatants of 8 selected LAB strains against various pathogens

Lactic acid bacteria strains	Antimicrobial activity against indicator strain expressed (AU mL <sup>-1</sup> )*					
	<i>Staphylococcus aureus</i>	<i>Candida albicans</i>	<i>Salmonella senftenberg</i>	<i>Escherichia coli</i>	<i>Klebsiella pneumoniae</i>	<i>Clostridium botulinum</i>
	NCTC 10788	ATCC MYA-2876	ATCC 8400	BA 12296	ATCC 12296	ATCC 3584
<i>L. brevis</i> NRRL B-4527	400	200	1600	800	6400	400
<i>S. thermophilus</i> BLM 58	400	200	800	800	400	200
<i>P. acidilactici</i> ATCC 8042	1600	400	800	1600	6400	200
<i>L. rhamnosus</i> CCUG 1452	200	0	3200	400	200	0
<i>L. curvatus</i> ATCC 51436	200	0	400	200	200	0
<i>L. lactis</i> subsp. <i>lactis</i> DSM 20481	200	200	400	800	400	800
<i>L. plantarum</i> DMSZ 20079	800	200	200	200	800	0
<i>L. plantarum</i> TF103	800	200	800	800	6400	200

\*Activity units/mL cell-free supernatant were calculated according to the following equation: (1000/d) × D, where, D is the two-fold dilution factor and d is the amount of supernatant used

Table 3: Survival of LAB strains under simulated gastric juice pH 2 conditions at 37 °C

Strains	Mean of viable count (log <sub>10</sub> CFU mL <sup>-1</sup> ) ± SD*				Surviving (%)
	Time of exposure (h)				
	0	1	2	3	
<i>P. acidilactici</i> ATCC 8042	8.12 ± 0.09 <sup>b</sup>	7.77 ± 0.22 <sup>a</sup>	6.93 ± 0.11 <sup>a</sup>	6.41 ± 0.05 <sup>a</sup>	78.94 ± 0.7 <sup>a</sup>
<i>L. lactis</i> subsp. <i>lactis</i> DSM 20481	8.06 ± 0.05 <sup>b</sup>	7.32 ± 0.04 <sup>bc</sup>	6.12 ± 0.11 <sup>b</sup>	5.75 ± 0.19 <sup>b</sup>	71.33 ± 2.07 <sup>b</sup>
<i>S. thermophilus</i> BLM 58	8.15 ± 0.15 <sup>b</sup>	7.24 ± 0.07 <sup>c</sup>	6.29 ± 0.03 <sup>b</sup>	5.38 ± 0.05 <sup>c</sup>	66.01 ± 0.77 <sup>c</sup>
<i>L. plantarum</i> TF103	8.25 ± 0.08 <sup>ab</sup>	7.73 ± 0.19 <sup>ab</sup>	7.10 ± 0.04 <sup>a</sup>	6.42 ± 0.04 <sup>a</sup>	78.94 ± 0.7 <sup>a</sup>
<i>L. brevis</i> NRRL B-4527	8.20 ± 0.06 <sup>ab</sup>	7.18 ± 0.10 <sup>c</sup>	6.80 ± 0.25 <sup>a</sup>	6.28 ± 0.15 <sup>a</sup>	76.58 ± 1.55 <sup>a</sup>
<i>L. rhamnosus</i> CCUG 1452	8.18 ± 0.13 <sup>ab</sup>	6.95 ± 0.37 <sup>c</sup>	5.04 ± 0.42 <sup>d</sup>	3.78 ± 0.23 <sup>e</sup>	46.21 ± 2.6 <sup>e</sup>
<i>L. curvatus</i> ATCC 51436	8.37 ± 0.08 <sup>a</sup>	6.90 ± 0.32 <sup>c</sup>	4.93 ± 0.25 <sup>d</sup>	4.00 ± 0.19 <sup>e</sup>	47.78 ± 1.87 <sup>e</sup>
<i>L. plantarum</i> DMSZ20079	8.26 ± 0.10 <sup>ab</sup>	6.96 ± 0.34 <sup>c</sup>	5.71 ± 0.19 <sup>c</sup>	4.81 ± 0.20 <sup>d</sup>	58.23 ± 2.36 <sup>d</sup>

<sup>abcd</sup>Mean in the same column followed by different superscript letters are \*significantly different (p < 0.05)

Table 4: Survival of LAB strains in MRS broth supplemented with 0.3% bile salts after 0, 1, 2 and 3 h at 37 °C

Strains	Mean of viable count (log <sub>10</sub> CFU mL <sup>-1</sup> ) ± SD*				Surviving (%)
	Time of exposure (h)				
	0	1	2	3	
<i>P. acidilactici</i> ATCC 8042	8.31 ± 0.04 <sup>a</sup>	7.14 ± 0.12 <sup>bc</sup>	6.44 ± 0.07 <sup>b</sup>	5.96 ± 0.25 <sup>a</sup>	71.72 ± 3.23 <sup>a</sup>
<i>L. lactis</i> subsp. <i>lactis</i> DSM 20481	8.19 ± 0.18 <sup>a</sup>	7.81 ± 0.22 <sup>a</sup>	6.91 ± 0.18 <sup>a</sup>	6.16 ± 0.06 <sup>a</sup>	75.21 ± 2.18 <sup>a</sup>
<i>S. thermophilus</i> BLM 58	8.24 ± 0.07 <sup>a</sup>	6.98 ± 0.07 <sup>c</sup>	5.95 ± 0.073 <sup>cd</sup>	5.35 ± 0.035 <sup>b</sup>	64.92 ± 0.99 <sup>b</sup>
<i>L. plantarum</i> TF103	8.12 ± 0.05 <sup>a</sup>	6.89 ± 0.17 <sup>c</sup>	6.15 ± 0.08 <sup>c</sup>	6.04 ± 0.14 <sup>a</sup>	74.38 ± 2.1 <sup>a</sup>
<i>L. brevis</i> NRRL B-4527	8.12 ± 0.14 <sup>a</sup>	7.07 ± 0.14 <sup>bc</sup>	6.87 ± 0.20 <sup>a</sup>	6.11 ± 0.09 <sup>a</sup>	75.24 ± 2.48 <sup>a</sup>
<i>L. rhamnosus</i> CCUG 1452	8.14 ± 0.16 <sup>a</sup>	7.26 ± 0.07 <sup>b</sup>	6.06 ± 0.07 <sup>cd</sup>	4.93 ± 0.22 <sup>c</sup>	60.56 ± 2.7 <sup>c</sup>
<i>L. curvatus</i> ATCC 51436	8.22 ± 0.15 <sup>a</sup>	6.65 ± 0.14 <sup>d</sup>	5.33 ± 0.07 <sup>e</sup>	4.11 ± 0.09 <sup>e</sup>	50.00 ± 1.98 <sup>d</sup>
<i>L. plantarum</i> DMSZ 20079	8.16 ± 0.11 <sup>a</sup>	7.09 ± 0.03 <sup>bc</sup>	5.81 ± 0.21 <sup>d</sup>	4.63 ± 0.16 <sup>d</sup>	56.74 ± 2.25 <sup>c</sup>

<sup>abcd</sup>Mean in the same column followed by different superscript letters are \*significantly different (p < 0.05)

**In vitro cell adherence of LAB strains:** The adhesion ability of LAB strains with Caco-2 cell line were observed by inverted microscope after Giemsa staining shown in Fig. 1. Data of adhesion (%) were summarized in Fig. 2. *Pediococcus acidilactici* ATCC 8042, *L. brevis* NRRL B-4527 and *S. thermophilus* BLM 58 showed significant (p < 0.05) adhesion percentages of 17.2 ± 2.11, 15.23 ± 2.14 and 12.9 ± 2.51%, respectively. Adherence of LAB strains to

gastrointestinal tract and their ability to resist the elimination by peristalsis are required factors to maintain their probiotic efficacy, therefore, strains *P. acidilactici* ATCC 8042, *L. brevis* NRRL B-4527 and *S. thermophilus* BLM 58 can potentially used as commercial probiotics. Further future investigation will required to determine the complex cell adhesion between the LAB membrane and interacting cell surface of mammalian cell line.




Fig. 1(a-d): Adhesion of selected LAB strains on Caco-2 cell line observed under inverted microscope (200x) after Giemsa staining. (a) Control Caco-2 cell line, treated Caco-2 cells with (b) *P. acidilactici* ATCC 8042, (c) *L. plantarum* TF103, (d) *L. brevis* NRRL B-4527, (e) *S. thermophilus* BLM 58, (f) *L. plantarum* DMSZ20079, (g) *L. Lactis* subsp. *lactis* DSM 20481, (h) *L. curvatus* ATCC 51436 and (i) *L. rhamnosus* CCUG 1452 for 2 h at 37°C  
The arrows indicate the attachment of bacterial cell to the mammalian Caco-2 cells




Fig. 2: Adhesion (%) of LAB strains on Caco-2 cell line




Fig. 3: Scavenging activity on DPPH free radicals by intact cells of LAB strains incubated at 30 °C for 24 h  
Each value is expressed as Mean ± SD (n = 3)

Table 5: Resistance of LAB strains at different hydrogen peroxide concentrations

Strains	Hydrogen peroxide concentration			
	Control	0.4 mM	0.7 mM	1 mM
<i>S. thermophilus</i> BLM 58	1.79 ± 0.176 <sup>a</sup>	1.13 ± 0.10 <sup>cd</sup>	0.76 ± 0.06 <sup>cd</sup>	0.69 ± 0.09 <sup>a</sup>
<i>L. plantarum</i> TF103	1.50 ± 0.28 <sup>bc</sup>	1.19 ± 0.1422 <sup>bcd</sup>	1.11 ± 0.166 <sup>a</sup>	0.88 ± 0.118 <sup>a</sup>
<i>L. plantarum</i> DMSZ 20079	1.41 ± 0.60 <sup>c</sup>	1.09 ± 0.13 <sup>d</sup>	0.87 ± 0.12 <sup>bc</sup>	0.43 ± 0.11 <sup>b</sup>
<i>P. acidilactici</i> ATCC 8042	1.85 ± 0.07 <sup>a</sup>	1.35 ± 0.13 <sup>abc</sup>	1.25 ± 0.06 <sup>a</sup>	0.80 ± 0.09 <sup>a</sup>
<i>L. rhamnosus</i> CCUG 1452	1.43 ± 0.06 <sup>c</sup>	1.15 ± 0.08 <sup>cd</sup>	0.75 ± 0.03 <sup>cd</sup>	0.27 ± 0.05 <sup>b</sup>
<i>L. brevis</i> NRRL B-4527	1.69 ± 0.09 <sup>ab</sup>	1.24 ± 0.10 <sup>bcd</sup>	1.06 ± 0.04 <sup>ab</sup>	0.76 ± 0.16 <sup>a</sup>
<i>L. lactis</i> subsp. <i>lactis</i> DSM 20481	1.87 ± 0.09 <sup>a</sup>	1.46 ± 0.12 <sup>a</sup>	1.23 ± 0.22 <sup>a</sup>	0.85 ± 0.06 <sup>a</sup>
<i>L. curvatus</i> ATCC 51436	1.70 ± 0.06 <sup>ab</sup>	1.39 ± 0.07 <sup>ab</sup>	0.64 ± 0.11 <sup>d</sup>	0.37 ± 0.06 <sup>b</sup>

Result are expressed as Mean ± SD, each value is the average of three experiments each was carried out in duplicate. The absorbance was measured at 624 nm.  
<sup>abcd</sup>Mean in the same column followed by different superscript letters are significantly different (p < 0.05)

### Evaluation of antioxidant activity of LAB strains

**Resistance of intact cells to hydrogen peroxide:** All eight strains showed tolerance to 0.4 mM hydrogen peroxide for 8 h with variations in viability. The *L. plantarum* TF103, *L. brevis* NRRL B-4527, *P. acidilactici* ATCC 8042 and *L. lactis* subsp. *Lactis* DSM 20481 showed maximum resistance against hydrogen peroxide with optical densities of more than 0.7 after incubation for 8 h with 1.0 mM hydrogen peroxide, whereas, strains, *L. rhamnosus* CCUG 1452 and *L. plantarum* DMSZ 20079 showed the highest sensitivity. While *L. curvatus* ATCC 51436 showed resistance at 0.4 mM while sensitive at 1.0 mM hydrogen peroxide (Table 5).

### Scavenging activities of intact LAB strains against DPPH:

The DPPH free radical scavenging activities of the LAB strains measured at 10<sup>10</sup>, 10<sup>9</sup> and 10<sup>8</sup> CFU mL<sup>-1</sup> is shown in Fig. 3. *Pediococcus acidilactici* ATCC 8042 showed the highest radical scavenging activity (67.5%), followed by

*S. thermophilus* BLM 58, *L. brevis* NRRL B-4527 and *L. lactis* subsp. *Lactis* DSM 20481 (63.46, 57.05 and 49.35%, respectively, at a concentration of 10<sup>10</sup> CFU mL<sup>-1</sup>). However, all strains showed lower DPPH radical scavenging activities at 10<sup>8</sup> CFU mL<sup>-1</sup>.

### Scavenging activities of bacterial lysate and supernatant of LAB strains against DPPH, ABTS and hydroxyl radicals:

The bacterial lysates (BL) and supernatants of the tested LAB (CFS) showed remarkably stronger scavenging activity for ABTS than for DPPH. Overall, the bacterial lysates (BL) and supernatants of the tested LAB (CFS) showed remarkably stronger scavenging activity for hydroxyl radical than for DPPH. The BL and CFS of *S. thermophilus* BLM 58 exhibited the highest antioxidant activity among all tested strains (p > 0.05) (Table 6). The bacterial lysate of *S. thermophilus* BLM 58 had the lowest IC<sub>50</sub> values of 1.18 ± 0.05 µg mL<sup>-1</sup> in ABTS scavenging and its CFS had the lowest IC<sub>50</sub> values of 5.57 ± 0.19 µg mL<sup>-1</sup> in DPPH.

Table 6: Scavenging activities of bacterial lysate and supernatant of LAB strains against DPPH, ABTS and hydroxyl radicals

Lactic acid bacteria strains	DPPH (IC <sub>50</sub> µg mL <sup>-1</sup> )		ABTS (IC <sub>50</sub> µg mL <sup>-1</sup> )		Hydroxyl radical (IC <sub>50</sub> µg mL <sup>-1</sup> )	
	BL	CFS	BL	CFS	BL	CFS
<i>P. acidilactici</i> ATCC 8042	7.25±0.39 <sup>b</sup>	8.60±0.70 <sup>b</sup>	1.66±0.07 <sup>c</sup>	7.28±0.48 <sup>d</sup>	4.92±0.24 <sup>c</sup>	6.42±0.17 <sup>c</sup>
<i>L. plantarum</i> TF103	8.89±0.75 <sup>a</sup>	9.70±1.08 <sup>b</sup>	3.83±0.20 <sup>b</sup>	9.57±0.56 <sup>b</sup>	6.40±0.188 <sup>a</sup>	11.06±1.51 <sup>ab</sup>
<i>L. plantarum</i> DMSZ20079	9.32±0.84 <sup>a</sup>	12.99±2.06 <sup>a</sup>	7.63±0.57 <sup>a</sup>	12.04±0.45 <sup>a</sup>	6.32±0.48 <sup>a</sup>	11.72±1.82 <sup>a</sup>
<i>L. rhamnosus</i> CCUG 1452	9.64±0.71 <sup>a</sup>	11.96±1.64 <sup>a</sup>	7.85±0.49 <sup>a</sup>	11.78±0.86 <sup>a</sup>	5.71±0.16 <sup>b</sup>	12.56±1.18 <sup>a</sup>
<i>S. thermophilus</i> BLM 58	5.38±0.37 <sup>c</sup>	5.57±0.19 <sup>c</sup>	1.18±0.05 <sup>c</sup>	7.03±0.38 <sup>d</sup>	3.99±0.18 <sup>d</sup>	5.63±0.27 <sup>c</sup>
<i>L. Lactis</i> subsp. <i>lactis</i> DSM 20481	5.78±0.42 <sup>c</sup>	5.71±0.24 <sup>c</sup>	1.22±0.02 <sup>c</sup>	7.66±0.45 <sup>cd</sup>	4.78±0.22 <sup>c</sup>	6.15±0.33 <sup>c</sup>
<i>L. curvatus</i> ATCC 51436	9.38±0.73 <sup>a</sup>	12.55±1.81 <sup>a</sup>	8.33±0.80 <sup>a</sup>	11.11±0.81 <sup>a</sup>	6.44±0.20 <sup>a</sup>	9.33±0.86 <sup>b</sup>
<i>L. brevis</i> NRRL B-4527	7.02±0.47 <sup>b</sup>	6.09±0.37 <sup>c</sup>	1.40±0.04 <sup>c</sup>	8.41±0.33 <sup>c</sup>	4.91±0.25 <sup>c</sup>	7.07±0.39 <sup>c</sup>

CFS: Cell free supernatant, BL: Bacterial lysate. Result are expressed as mean±SD, each value is the average of three experiments each was carried out in duplicate. <sup>abcd</sup>Mean in the same column followed by different superscript letters are significantly different (p<0.05)

Table 7: IC<sub>50</sub> and EC<sub>100</sub> doses (µg mL<sup>-1</sup>) of each investigated probiotic lysates toward HDF cells

Lactic acid bacteria strains	IC <sub>50</sub>	EC <sub>100</sub>
<i>P. acidilactici</i> ATCC 8042	198.07±1.45 <sup>a</sup>	103.56±2.7 <sup>ace</sup>
<i>L. curvatus</i> ATCC 51436	151.98±6.03 <sup>b</sup>	60.28±2.9 <sup>b</sup>
<i>L. plantarum</i> TF103	185.55±3.05 <sup>a</sup>	119.30±3.6 <sup>cd</sup>
<i>L. plantarum</i> DMSZ20079	228.45±0.59 <sup>c</sup>	127.08±2.1 <sup>d</sup>
<i>L. Lactis</i> subsp. <i>lactis</i> DSM 20481	194.34±2.6 <sup>a</sup>	94.31±9.2 <sup>e</sup>
<i>L. rhamnosus</i> CCUG 1452	185.57±1.34 <sup>a</sup>	93.31±7.3 <sup>e</sup>
<i>L. brevis</i> NRRL B-4527	190.47±8.8 <sup>a</sup>	101.63±8.2 <sup>e</sup>
<i>S. thermophilus</i> BLM 58	467.89±9.6 <sup>d</sup>	228.60±8.5 <sup>f</sup>

All values were expressed as Mean±SEM. Different letters between bacterial lysates within the same column are significantly different at p<0.05

Table 8: Anticancer activity of the studied bacterial lysates against human cancer cell lines in the term of IC<sub>50</sub> (µg mL<sup>-1</sup>)

Lactic acid bacteria strains	Human cancer cell lines			
	Caco-2	MCF-7	HepG-2	PC-3
<i>P. acidilactici</i> ATCC 8042	16.30±5.1 <sup>e</sup>	59.66±9.5 <sup>e</sup>	53.60±5.4 <sup>d</sup>	54.41±2.4 <sup>f</sup>
<i>L. curvatus</i> ATCC 51436	206.60±3.4 <sup>a</sup>	259.79±1.1 <sup>a</sup>	101.10±9.8 <sup>bc</sup>	200.21±5.2 <sup>b</sup>
<i>L. plantarum</i> TF103	77.40±4.5 <sup>b</sup>	275.81±6.8 <sup>a</sup>	111.50±19.9 <sup>b</sup>	308.57±8.6 <sup>a</sup>
<i>L. plantarum</i> DMSZ20079	51.20±4.6 <sup>c</sup>	279.05±19.3 <sup>a</sup>	193.32±9.7 <sup>a</sup>	288.11±9.1 <sup>a</sup>
<i>L. Lactis</i> subsp. <i>lactis</i> DSM 20481	29.50±2.5 <sup>d</sup>	136.10±4.8 <sup>c</sup>	56.90±5.12 <sup>d</sup>	137.41±6.4 <sup>d</sup>
<i>L. rhamnosus</i> CCUG 1452	30.40±3.4 <sup>d</sup>	197.80±5.3 <sup>b</sup>	94.94±9.2 <sup>bc</sup>	158.53±8.5 <sup>c</sup>
<i>L. brevis</i> NRRL B-4527	40.86±2.4 <sup>cd</sup>	91.14±6.8 <sup>d</sup>	74.26±3.5 <sup>cd</sup>	92.37±3.4 <sup>e</sup>
<i>S. thermophilus</i> BLM 58	16.90±1.1 <sup>e</sup>	48.54±7.04 <sup>e</sup>	41.18±8.7 <sup>d</sup>	64.81±3.97 <sup>f</sup>

All values were expressed as Mean±SEM. Different letters between bacterial lysates within the same column are significantly different at p<0.05

### Cytotoxicity and anticancer effect of the LAB lysates:

As shown in Table 7, all bacterial lysates were safe in terms of EC<sub>100</sub> (above 90 µg mL<sup>-1</sup>), except *L. curvatus* ATCC 51436, which showed the lowest EC<sub>100</sub> value (60.28 µg mL<sup>-1</sup>) toward HDF cells. *Streptococcus thermophilus* BLM 58 had the highest IC<sub>50</sub> value (467.89 µg mL<sup>-1</sup>), which was significantly different (p<0.05) from the IC<sub>50</sub> values (<230 µg mL<sup>-1</sup>) of the other tested bacterial lysates.

Additionally, the bacterial lysates of *S. thermophilus* BLM 58 possessed the lowest IC<sub>50</sub> values (48.5 and 41.2 µg mL<sup>-1</sup>) against tested MCF-7 and HepG-2 cancer cell lines as shown in Table 8. There were no significant differences in the IC<sub>50</sub> values of *S. thermophilus* BLM 58 lysate and *P. acidilactici* ATCC 8042 against the four cancer cell lines (16.3, 59.7, 53.6 and 54.4 µg mL<sup>-1</sup>). The lowest IC<sub>50</sub> values of *P. acidilactici* ATCC 8042 and *S. thermophilus* BLM 58 reflect

the highest anticancer activity of both lysates (Table 8). The potent anticancer effects of these four bacterial lysates (*P. acidilactici* ATCC 8042, *S. thermophilus* BLM 58, *L. brevis* NRRL B-4527 and *L. lactis* subsp. *lactis* DSM 20481) were evident as shown by severe alterations in the morphology of the treated cancer cell lines, especially the *P. acidilactici* ATCC 8042 and *S. thermophilus* BLM 58-treated cancer cells, compared with the controls (untreated cancer cells, Fig. 4). More importantly, the SI values of *S. thermophilus* BLM 58 for cancer cells were the highest among all the studied bacterial lysates against the four cancer cells, especially Caco-2 cells (SI = 27.8). The next highest SI values were obtained from *P. acidilactici* ATCC 8042; however, the SI value against HepG-2 cells was not significantly different from those of *L. lactis* subsp. *lactis* DSM 20481 and *L. brevis* NRRL B-4527 toward those cells (Fig. 5). The anticancer






Fig. 4(a-d): Morphological changes of (a) Caco-2, (b) MCF-7, (c) HepG-2 and (d) PC-3 cell lines after exposure for 72 h to (I) *P. acidilactici* ATCC 8042, (II) *L. lactis* subsp. *lactis* DSM 20481, (III) *L. brevis* NRRL B-4527, (IV) *S. thermophilus* BLM 58 (Magnification x200)

mechanisms of the most effective probiotic lysates (*S. thermophilus*, *P. acidilactici*, *L. lactis* subsp. *Lactis* and *L. brevis*) were investigated using flow cytometry. Results in Fig. 6 showed the high percentages of annexin-stained apoptotic HepG-2 cells treated separately with the four most anticancer probiotic lysates compared with untreated HepG-2 cell controls. This result confirmed

that the anticancer activity of probiotic lysate samples was mediated through the induction of apoptosis. Table 9 showed that the total percentage of apoptotic *S. thermophilus*-treated HepG-2 cells ( $68.95 \pm 1.53\%$ ) was significantly (p-value 0.05) higher than those of *P. acidilactici*, *L. lactis* subsp. *lactis*- and *L. brevis*-treated HepG-2 cells.




Fig. 5: Selectivity index of the studied bacterial lysates toward human cancer cell lines




Fig. 6(a-e): Flow cytometric analysis of (a) Control HepG-2 cell line. Treated HepG-2 cell line with (b) *S. thermophilus* BLM 58, (c) *L. lactis* subsp. *lactis* DSM 20481, (d) *P. acidilactici* ATCC 8042 and (e) *L. brevis* NRRL B-4527 for 72 h

Table 9: Apoptosis (%) of HepG-2 cells before and after treatment with selected probiotic lactic acid bacteria

HepG-2	Early apoptosis	Late apoptosis	Total apoptosis
Control	0.015 ± 0.005 <sup>a</sup>	2.09 ± 0.1 <sup>a</sup>	2.11 ± 0.1 <sup>a</sup>
<i>P. acidilactici</i> ATCC8042	23.400 ± 1.4 <sup>b</sup>	37.42 ± 2.5 <sup>b</sup>	60.82 ± 3.93 <sup>b</sup>
<i>L. Lactis</i> subsp. <i>lactis</i> DSM20481	24.600 ± 0.69 <sup>b</sup>	27.98 ± 0.9 <sup>c</sup>	52.59 ± 1.6 <sup>c</sup>
<i>L. brevis</i> NRRLB-4527	26.320 ± 1.31 <sup>b</sup>	19.70 ± 0.3 <sup>d</sup>	46.02 ± 1.01 <sup>c</sup>
<i>S. thermophilus</i> BLM58	4.800 ± 3.4 <sup>c</sup>	19.70 ± 2.32 <sup>d</sup>	68.95 ± 1.53 <sup>e</sup>

All values were expressed as Mean ± SEM. Different letters between bacterial lysates within the same column are significantly different at p < 0.05

Table 10: Bivariate correlation of antioxidant activities and anti-cancer activity of LAB lysates

Relationship	Correlation coefficient	p-value (2-Tailed)
DPPH and anti-cancer activity (HepG-2 cells)	0.697**	0.000
DPPH and anti-cancer activity (MCF-7cells)	0.788**	0.000
DPPH and anti-cancer activity (PC-3cells)	0.670**	0.000
DPPH and anti-cancer activity (Caco-2cells)	0.490*	0.015

\*\*Correlation is significant at the 0.01 level (2-tailed), \*Correlation is significant at the 0.05 level (2-tailed)

### Correlation between anticancer activity and antioxidant activity:

The Pearson correlation coefficients between the tests for antioxidant and anticancer activity were calculated and are presented in Table 10. Significant relationships between antioxidant activity and anticancer activity (correlation coefficient,  $r = -0.697, 0.788, 0.670, 0.490, p < 0.01$ ) for the HepG-2, MCF-7, PC-3 and Caco-2 cell lines, respectively, indicated that high antioxidant activity was an important significant factor for determining the anticancer activity of bacterial lysate extracts. The anticancer activity of LAB lysates may be attributed to the antioxidant compounds possessing potent radical scavenging activities.

## DISCUSSION

Probiotic strains can be utilized as bio-preservatives and functional food supplements. Consequently, the search for natural, stable, safe, antimicrobial, antioxidant and anticancer agents have become a subject of interest as alternatives to artificial compounds.

The antimicrobial properties of these LAB strains were tested against seven dominant food borne pathogenic bacteria. The observed antimicrobial activity must be due to the presence of active antimicrobial compounds secreted in culture media. The LAB strains are 'recognized as safe' (GRAS). Therefore, their use in food as bio-preservatives has received much interest. These probiotics may be able to resist SGJ (pH 2) and bile in the upper part of the intestine (0.3%), so they can be used as dietary supplements. This property allowed strains to survive for more extended periods of time in high-acid foods without reductions in humans<sup>22</sup>.

The adhesion percentages of *Lb. plantarum* strains on HT-29 cells have been reported<sup>23</sup> to be 5-13%. Probiotic strains *L. plantarum* STIII and *L. plantarum* Lp9 showed adhesion percentages of  $13 \pm 0.2$  and  $7.4 \pm 1.3\%$ , respectively, with Caco-2 cells<sup>24</sup>. These results indicated the ability of *P. acidilactici* ATCC 8042, *L. brevis* NRRL B-4527, *S. thermophilus* BLM 58 and *L. plantarum* TF103 to adhere to the gastrointestinal tract and resist their immediate

elimination by peristalsis. Their ability to adhere to colon cells is crucial in maintaining probiotic efficacy. Therefore, these strains can potentially be used as commercial probiotics.

Hydrogen peroxide is a weak oxidative agent that causes oxidative damage, especially to DNA, due to its production of hydroxyl radicals<sup>25</sup>. The *L. plantarum* C88 and *L. fermentum* have been reported to be highly resistant to hydrogen<sup>25,26</sup>. The mechanism responsible for the different degrees of resistance of current tested LAB probiotic strains to hydrogen peroxide remains unclear.

The DPPH free radical scavenging activities indicated that the intact cells of *P. acidilactici* ATCC 8042 showed strong antioxidant activity *in vitro*, which was similar to the antioxidant activity of *Lactobacillus plantarum* C88 described by Li *et al.*<sup>25</sup>. These results confirmed those of Shen *et al.*<sup>27</sup>, who showed that proteins extracted from *Bifidobacterium animalis* 01 cells possessed antioxidant activity *in vitro*.

Hydroxyl radicals as well have been considered the most dangerous ROS responsible for oxidative damage to biomolecules. Copper  $\text{Cu}^{2+}$  and Iron $^{2+}$  ions are critical for hydroxyl radical production through fenton reaction. Antioxidants chelation of these ions prevent the formation of hydroxyl radicals<sup>28</sup>. A few LAB strains, such as *Bifidobacterium longum* 15708, *Streptococcus thermophilus*<sup>6</sup> 821 and *L. casei*<sup>29</sup> KCTC 3260 have been described to possess antioxidant activity in removing transition metal ions that would otherwise participate in hydroxyl radical generation through fenton-type reactions. In the present study, the bacterial lysate and supernatant of *S. thermophilus* BLM 58 exhibited strong HRS activity, likely due to their capability to chelate metal ions, such as  $\text{Fe}^{2+}$  and  $\text{Cu}^{2+}$ .

By the same token, the supernatants and bacterial lysates of *S. thermophilus* BLM 58 and *L. lactis* subsp. subsp. *lactis* DSM 20481 demonstrated the strongest scavenging activity toward the DPPH radical. These properties are very important in the food industry.

Previous clinical studies have emphasized the safe administration of LAB to healthy adults and even to immune-compromised patients and premature infants, without any side effects<sup>30</sup>. Several previous results have reported the antitumor activity of many LAB species, such as *Lactobacillus acidophilus*, *Lactobacillus casei*<sup>31</sup> and *P. acidilactici*<sup>32</sup>. The current study reported for the first time, the potent anticancer effects of *S. thermophilus* against colon, breast, liver and prostate cancer cells. These results with agreement with other reports that reviewed that *Lactobacillus acidophilus* has antioxidant properties and is

capable of inducing cytotoxicity in colon cancer cells via the down-regulation of tumor angiogenesis and metastasis<sup>33</sup>. *Lactobacillus* species exhibited remarkable anticancer potency against colon, breast, cervical and gastric cancer cell lines via the induction of apoptosis without affecting normal human endothelial cells<sup>34</sup>. Thus, the anticancer activity of probiotic strains seems to be mediated through the induction of apoptosis in cancer cells. The anticancer activity of these strains may be promising for use in supported therapy or cancer prevention<sup>35</sup>. The present results indicate that *S. thermophilus* BLM 58 had the most effective and safe antioxidant and anticancer probiotic lysate. *Streptococcus thermophilus* BLM 58 exhibited the highest apoptosis-dependent anticancer potency, which may be attributed to its strong antioxidant effects. This deprives cancer cells of free radicals and maintains uncontrolled proliferation. In this study, the bacterial lysate extracts of *S. thermophilus* BLM 58 had a promising antioxidant and the anticancer potent, with a high correlation factor ( $r = 0.788$ ). Further researches will required to confirm the antioxidant and the anticancer potent of functional food application in induced animal models.

### CONCLUSION

The present study showed that *S. thermophilus* BLM 58 and *P. acidilactici* ATCC 8042 had the strongest antioxidant potentials. These results indicated that the functional compounds in the cultured broth and bacterial lysates were different. The selected probiotic strains, particularly *S. thermophilus* BLM 58, *L. lactis* subsp. *lactis* DSM 20481, *P. acidilactici* ATCC 8042 and *L. brevis* NRRL B-4527 are considered better strains for functional food applications with potentially antioxidant and anticancer activity.

### SIGNIFICANCE STATEMENT

The present study aimed to characterize probiotic LAB strains and assess their antimicrobial, antioxidant and anticancer efficacies. The selected probiotic strains, particularly *S. thermophilus* BLM 58, *L. lactis* subsp. *lactis* DSM 20481, *P. acidilactici* ATCC 8042 and *L. brevis* NRRL B-4527, are considered better strains for functional food applications because they produce antioxidant compounds. The current study demonstrated for the first time the high capacity of *S. thermophilus* BLM 58 to have anticancer effects against cancer cells from four types of cancerous cell lines. This may be a promising finding for future cancer treatments and in the prevention of cancer using natural probiotics.

### ACKNOWLEDGMENTS

The authors acknowledge the Food Technology Department, Arid Lands Cultivation Research Institute, City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab, Alexandria, Egypt for funding the activities presented in this study.

### REFERENCES

1. Charteris, W.P., P.M. Kelly, L. Morelli and J.K. Collins, 1998. Development and application of an *in vitro* methodology to determine the transit tolerance of potentially probiotic *Lactobacillus* and *Bifidobacterium* species in the upper human gastrointestinal tract. *J. Applied Microbiol.*, 84: 759-768.
2. Muhammad, I., A.A. Ahmad and T. Shah, 2018. Health promoting and disease preventing properties of probiotics with special reference to lactobacillus: A review. *J. Probiot. Health*, Vol. 6. 10.4172/2329-8901.1000202.
3. Sharma, R., B. Bhaskar, B.S. Sanodiya, G.S. Thakur and P. Jaiswal *et al.*, 2014. Probiotic Efficacy and Potential of *Streptococcus thermophilus* modulating human health: A synoptic review. *IOSR J. Pharm. Biol. Sci.*, 9: 52-58.
4. Shehata, M.G., S.A. ElSohaimy, M.A. El-Sahn and M.M. Youssef, 2016. Screening of isolated potential probiotic lactic acid bacteria for cholesterol lowering property and bile salt hydrolase activity. *Ann. Agric. Sci.*, 61: 65-75.
5. Wiernasz, N., J. Cornet, M. Cardinal, M.F. Pilet, D. Passerini and F. Leroi, 2017. Lactic acid bacteria selection for biopreservation as a part of hurdle technology approach applied on seafood. *Front. Mar. Sci.*, Vol. 4. 10.3389/fmars.2017.00119.
6. Rahman, T., I. Hosen, M.M.T. Islam and H.U. Shekhar, 2012. Oxidative stress and human health. *Adv. Biosci. Biotechnol.*, 3: 997-1019.
7. Abdel-Razek, A.G., A.N. Badr and G.S. Mohamed, 2017. Characterization of olive oil By-products: antioxidant activity, its ability to reduce aflatoxigenic fungi hazard and its aflatoxins. *Annu. Res. Rev. Biol.*, 14: 1-14.
8. Cleveland, J., T.J. Montville, I.F. Nes and M.L. Chikindas, 2001. Bacteriocins: Safe, natural antimicrobials for food preservation. *Int. J. Food Microbiol.*, 71: 1-20.
9. Sah, B.N.P., T. Vasiljevic, S. McKechnie and O.N. Donkor, 2014. Effect of probiotics on antioxidant and antimutagenic activities of crude peptide extract from yogurt. *Food Chem.*, 156: 264-270.
10. Osuntoki, A. and I. Korie, 2010. Antioxidant activity of whey from milk fermented with *Lactobacillus* species isolated from Nigerian fermented foods. *Food Technol. Biotechnol.*, 48: 505-511.

11. De Man, J.C., M. Rogosa and M.E. Sharpe, 1960. A medium for the cultivation of lactobacilli. *J. Applied Bacteriol.*, 23: 130-135.
12. Barefoot, S.F. and T.R. Klaenhammer, 1983. Detection and activity of lactacin B, a bacteriocin produced by *Lactobacillus acidophilus*. *Applied Environ. Microbiol.*, 45: 1808-1815.
13. Shehata, M.G., A.N. Badr and S.A. El Sohaimy, 2018. Novel antifungal bacteriocin from *Lactobacillus paracasei* KC39 with anti-mycotoxigenic properties. *Biosci. Res.*, 15: 4171-4183.
14. Duary, R.K., Y.S. Rajput, V.K. Batish and S. Grover, 2011. Assessing the adhesion of putative indigenous probiotic lactobacilli to human colonic epithelial cells. *Indian J. Med. Res.*, 134: 664-671.
15. Kaushik, J.K., A. Kumar, R.K. Duary, A.K. Mohanty, S. Grover and V.K. Batish, 2009. Functional and probiotic attributes of an indigenous isolate of *Lactobacillus plantarum*. *PLoS ONE*, Vol. 4. 10.1371/journal.pone.0008099.
16. Lin, M.Y. and C.L. Yen, 1999. Antioxidative ability of lactic acid bacteria. *J. Agric. Food Chem.*, 47: 1460-1466.
17. Buchmeier, N., S. Bossie, C.Y. Chen, F.C. Fang, D.G. Guiney and S.J. Libby, 1997. SlyA, a transcriptional regulator of *Salmonella typhimurium*, is required for resistance to oxidative stress and is expressed in the intracellular environment of macrophages. *Infect. Immunity*, 65: 3725-3730.
18. He, Z.S., H. Luo, C.H. Cao and Z.W. Cui, 2004. Photometric determination of hydroxyl free radical in Fenton system by brilliant green. *Am. J. Chin. Clin. Med.*, 6: 236-237.
19. Rossini, K., C.P.Z. Norena, F. Cladera-Olivera and A. Brandelli, 2009. Casein peptides with inhibitory activity on lipid oxidation in beef homogenates and mechanically deboned poultry meat. *LWT-Food Sci. Technol.*, 42: 862-867.
20. Brand-Williams, W., M.E. Cuvelier and C. Berset, 1995. Use of a free radical method to evaluate antioxidant activity. *LWT-Food Sci. Technol.*, 28: 25-30.
21. Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods*, 65: 55-63.
22. Prasad, J., H. Gill, J. Smart and P.K. Gopal, 1998. Selection and characterisation of *Lactobacillus* and *Bifidobacterium* strains for use as probiotics. *Int. Dairy J.*, 8: 993-1002.
23. Kumar, R.S., P. Kanmani, N. Yuvaraj, K.A. Paari, V. Pattukumar and V. Arul, 2011. *Lactobacillus plantarum* AS1 binds to cultured human intestinal cell line HT-29 and inhibits cell attachment by enterovirulent bacterium *Vibrio parahaemolyticus*. *Lett. Applied Microbiol.*, 53: 481-487.
24. Chen, P., Q. Zhang, H. Dang, X. Liu and F. Tian *et al.*, 2014. Screening for potential new probiotic based on probiotic properties and  $\alpha$ -glucosidase inhibitory activity. *Food Control*, 35: 65-72.
25. Li, S., Y. Zhao, L. Zhang, X. Zhang and L. Huang *et al.*, 2012. Antioxidant activity of *Lactobacillus plantarum* strains isolated from traditional Chinese fermented foods. *Food Chem.*, 135: 1914-1919.
26. Wang, A.N., X.W. Yi, H.F. Yu, B. Dong and S.Y. Qiao, 2009. Free radical scavenging activity of *Lactobacillus fermentum in vitro* and its antioxidative effect on growing-finishing pigs. *J. Applied Microbiol.*, 107: 1140-1148.
27. Shen, Q., N. Shang and P. Li, 2011. *In vitro* and *in vivo* antioxidant activity of *Bifidobacterium animalis* 01 isolated from centenarians. *Curr. Microbiol.*, 62: 1097-1103.
28. Kao, T.H. and B.H. Chen, 2006. Functional components in soybean cake and their effects on antioxidant activity. *J. Agric. Food Chem.*, 54: 7544-7555.
29. Lee, J., K.T. Hwang, M.Y. Chung, D.H. Cho and C.S. Park, 2005. Resistance of *Lactobacillus casei* KCTC 3260 to Reactive Oxygen Species (ROS): Role for a metal ion chelating effect. *J. Food Sci.*, 70: m388-m391.
30. Sanders, M.E., L.M.A. Akkermans, D. Haller, C. Hammerman, J.T. Heimbach, G. Hormannsperger and G. Huys, 2010. Safety assessment of probiotics for human use. *Gut Microbes*, 1: 164-185.
31. Kailasapathy, K. and J. Chin, 2000. Survival and therapeutic potential of probiotic organisms with reference to *Lactobacillus acidophilus* and *Bifidobacterium* spp. *Immunol. Cell Biol.*, 78: 80-88.
32. Villarante, K.I., F.B. Elegado, S. Iwatani, T. Zendo, K. Sonomoto and E.E. de Guzman, 2011. Purification, characterization and *in vitro* cytotoxicity of the bacteriocin from *Pediococcus acidilactici* K2a2-3 against human colon adenocarcinoma (HT29) and human cervical carcinoma (HeLa) cells. *World J. Microbiol. Biotechnol.*, 27: 975-980.
33. Deepak, V., S. Ramachandran, R.M. Balahmar, S.R.K. Pandian, S.D. Sivasubramaniam, H. Nellaiah and K. Sundar, 2016. *In vitro* evaluation of anticancer properties of exopolysaccharides from *Lactobacillus acidophilus* in colon cancer cell lines. *In vitro Cell. Dev. Biol.-Anim.*, 52: 163-173.
34. Nami, Y., N. Abdullah, B. Haghshenas, D. Radiah, R. Rosli and A.Y. Khosroushahi, 2014. Assessment of probiotic potential and anticancer activity of newly isolated vaginal bacterium *Lactobacillus plantarum* 5BL. *Microbiol. Immunol.*, 58: 492-502.
35. Daniluk, U., 2012. Probiotics, the new approach for cancer prevention and/or potentialization of anti-cancer treatment? *J. Clin. Exp. Oncol.*, Vol. 1. 10.4172/2324-9110.1000e105.